

Legal disclaimer

- This presentation, which is personal to the recipient, has been prepared and produced by Orexo AB (publ) ("Orexo") solely for the benefit of investment analysis and may not be used for any purpose other than assessment of investments concerning Orexo. Unless otherwise stated, Orexo is the source for all data contained in this presentation. Such data is provided as at the date of this presentation and is subject to change without notice.
- This presentation does not constitute or form part of, and should not be construed as, an offer or invitation for the sale of or the subscription of, or a solicitation of any offer to buy or subscribe for, any securities, nor shall it or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any offer, contract, commitment or investment decision relating thereto, nor does it constitute a recommendation regarding the securities of Orexo
- The shares of Orexo have not been registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States (as such term is defined in Regulation S under the Securities Act) except pursuant to an exemption from, or a transaction not subject to, the registration requirements of the Securities Act or unless registered under the Securities Act.
- The information in this presentation has not been independently verified. No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy or completeness of the information or opinions contained herein. None of Orexo, any of its shareholders, or any of their respective subsidiary undertakings or affiliates or any of such person's directors, officers or employees, advisers or other representatives, accepts any liability whatsoever (whether in negligence or otherwise) arising, directly or indirectly, from the use of this presentation or otherwise arising in connection therewith.
- This presentation includes forward-looking statements. These forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance, achievements or industry results to be materially different from those expressed or implied by these forward-looking statements. Forward-looking statements speak only as of the date of this presentation and Orexo expressly disclaim any obligation or undertaking to release any update of, or revisions to, any forward-looking statements in this presentation as a result of any change in our expectations or any change in events, conditions or circumstances on which these forward-looking statements are based.
- This presentation is not a prospectus in accordance with the Swedish Financial Instruments Trading Act (Sw. lagen (1991:981) om handel med finansiella instrument) or any other Swedish laws or regulations. Neither the Swedish Financial Supervisory Authority (Sw. Finansinspektionen) nor any other Swedish regulatory body has examined, approved or registered this presentation.

Orexo in brief



HQ & Pipeline

Development of improved drugs based on well-known substances combined with innovative proprietary Drug Delivery technologies, such as amorphOX™.

US Pharma

Commercial US Pharma platform since 2013, incl. market access team and sales representatives who on a daily basis visit physicians, medical clinics and minor hospitals.



Digital Therapeutics

Evidence-based digital therapies grounded in cognitive behavioral therapy techniques, offer better treatment access for patients and improve their outcomes.

Confidential

DTx in brief

- ✓ Subsection of digital health
- ✓ Evidence-based therapeutic intervention
- ✓ Prevent, manage, or treat a medical disorder or disease
- ✓ Particularly applicable in the mental illness & addiction space
- ✓ Standalone or along with pharma treatment
- ✓ Available 24/7



Strong underlying trends will force the DTx market to gain traction

Healthcare systems challenged

Aging population and sky-rocketing costs are forcing the healthcare providers to rethink how to deliver healthcare to increase efficiency and value.



Widespread technology acceptance

Covid-19 has further pushed forward the ongoing tech revolution and the use of telemedicine is pervasive.

Consumers (patients) in the center

Patients want to be seen as consumers and requires holistic and customized treatments with access 24/7.



Value-based care

Providers will be rewarded based on the ability to add patient value. Analyzing RWE data pave the way for efficient allocation of resources.

Clinically proven DTx in collaboration with GAIA AG

Rooted in cognitive behavioral therapy techniques and based on AI technology offering a highly individualized intervention.

	modia	VORV!DA	deprexis®
Instructions for use	Opioid dependence	Alcohol misuse	Depression
Clinical evidence ¹	Ongoing randomized clinical trial, 400 patients	Evaluated in 1 randomized clinical trial, > 600 patients	Evaluated in 13 randomized clinical trials, > 2.800 patients
Length of treatment	6 months	6 months	3 months
Treatment method	Along with current standard of care including medication	Standalone or as a complement to current standard of care	Standalone or as a complement to current standard of care
FDA clearance	Will apply for a 510 k clearance, meanwhile launched under FDA's Public Health Emergency Use Authorization (EUA)	FDA cleared under the Emergency Use Authorization	FDA cleared under the enforcement disctretion

¹ View study results in Appendix

modia

Great, let's go!

The goal of this whole program is to teach you some special skills and exercises that support and empower you in your struggle against opioid dependency.



As your coach, I want to work with you in the most effective way I can.

So I wonder, Sreenadh, what kind of coach would you feel most comfortable with?

I want someone who's going to keep me in line and not let me off the hook. Like > a hard-as-nails drill sergeant who secretly thinks I'm his best cadet.

I want a coach who's gentle, patient, and, most importantly, a good listener. Like 🗦 Sally Field in every movie she's ever done.

modia

Yep. I think it's important that programs like me are scientifically evaluated by doctors and patients. Otherwise, you can't really know if they work or not. But if you want, here's some more specific data to back what we're doing here.

So, Sreenadh, before we get into this, there's a couple of things you should know regarding any risks or safety issues related to using this program. Think of this as the fine print, but I wanna be up front about everything.

First, keep in mind that just because you're using this program, it doesn't mean that you should change or stop any other treatments you might be getting.


MODIA isn't supposed to replace other treatments or be a substitute for them. So if you're taking medication, for example, please don't change that without consulting your doctor first.

Gotcha.



Sample Cognitive Behavioral Techniques Used by MODIA®

Mental Imagery Relaxation Exercise Great! You know what to do. Whenever you're ready, just click on the icon to listen. Juggling green and red balls ☐ That was interesting. I really liked it.



Homework Assignments Practicing Skills

So, is that still accurate, or have you moved to a different stage?

Remember, this is a wheel, so moves in both directions are expected.

Where would you place yourself on the wheel today?

- ☐ Pre-contemplation. Quitting isn't a realistic option for me.
- ☐ Contemplation: I'm still thinking hard about whether I can do it or not.
- ☐ Planning: I'm committed to living a healthy lifestyle, without opioids, but I need to figure out how.
- ☐ Action: I've made that change, but it's all very recent.
- ☐ Maintenance: I've quit a pretty long time ago and I'm leading a healthy lifestyle now, without opioids.

Orexos digital therapies are different

✓ GAIA is a veteran in digital therapies

- 20 years of experience developing more than 70 products, many available globally
- **✓** Extensive development behind each product
- Developed by psychologist and doctors, in close collaboration with healthcare providers and patients

✓ Proven effectiveness

19 RCTs have shown the effectiveness of the products and the technology platform Broca®

✓ A virtual expert


- Guide the user step-by-step, simulating 1:1 coaching, training or therapy sessions customized to each user
- ✓ Aggregated information to the payer/HCP
- Outcome monitored and measured using established diagnostic tools
- ✓ Meet the highest standard of data privacy
- All patient data is treated as strictly confidential

Orexo is open for a flexible and outcomes based business model

Developing the DTx is just a first step bringing them to the US market

A scalable distribution platform meeting all requirements for data integrity is essential







Real world data and analytics

¹ Developed for Orexo by Accenture on their INTIENT™ Platform, the solution is proprietary for Orexo.

Digital therapies won't reach their full potential without reimbursement

Several possible reimbursemet pathways are emerging

Reimbursement Route

The Prescription Model

The Medical Benefit Model


Requirement

- FDA approval as a prescription digital therapy (PDT)
- Pharmacy benefit coverage pathway
- HCPs integrate
 DTx in
 treatment
 programs
- CPT codes defined by AMA/CMS

Orexo's Activities

- ✓ Active member in the DTx alliance to enable change in Washington
- ✓ Randomized clinical trial for MODIA™ underway, early market entry via FDA EUA
- ✓ Partnership with IDNs such as Trinity Health, Benefis Health System
- ✓ Engagement of payers and generation of RWE e.g.

 Magellan



Final step in the commercialization is reaching the patients –

orexo

Orexo works through wellestablished partners



Consumers

Moving from direct to consumer promotion to distribution through established and well-known partners







Healthcare providers

Continued and intensified work with Trinity Health to establish feasible reimbursement pathways integrating DTx into reimbursed treatment programs







Employers

Partnering with providers offering a broad range of services to employers

E-HBS just **miine**

135 million visitors in Q3 2021 at Walgreens Find Care®1

What to expect from DTx?

Digital Therapies are a new disruptive tool in healthcare

Significant interest exist and viable reimbursement pathways are evolving

The development of the overall market is still in its infancy

